News

PD Online Research Exclusives

Etiology, Clinical & Biological Features, Therapeutic Development
PDOR Spotlight

Here's a list of hot items you don't want to miss, found only on PD Online Research. Members:  log in and move the discussion forward by posting a response. Also, look at Editor's Choice to see more great posts from our members on Parkinson's disease science.

 

 

 

 

Q&A with Dr. Paul Larson: Neurosurgical Approaches for Treating Parkinson's Disease

Dr. Paul Larson (UCSF) and Dr. Jamie L. Eberling (MJFF) discuss the current state of neurosurgical approaches for treating PD.

 

New mouse model for non-motor symptoms: Q&A with Dr. Gary Miller

Dr. Gary Miller and Dr. Todd Sherer discuss Dr. Miller's new publication in the Journal of Neuroscience (published Jun 24), in which he describes a new VMAT2-deficient mouse model of the non-motor symptoms of Parkinson's disease.

 

Interview with Dr. J. William Langston: iPS cells as disease models

Dr. Langston spoke with Dr. Michael Rogan and Dr. Holli Kawadler of MJFF about the future of induced pluripotent stem cells (iPSCs). Cell replacement therapy or disease modeling? Don't miss the exclusive interview!

 

Cell Death by Dopamine, Calcium and Alpha-synuclein: Q&A with Dr. David Sulzer

Dr. David Sulzer and Dr. Mark Frasier discuss Dr. Sulzer's recent publication in Neuron: Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons.

 

Live Reports from the Movement Disorder Society's 13th International Congress

Alison Urkowitz of MJFF was live on the scene in Paris, France to give us daily reports on MDS.

 

First published LRRK2 mutation mouse model of PD: Q&A with Dr. Chenjian Li

Dr. Li talks to Dr. Kirsten Carlson about his brand new LRRK2 mouse model, discussing both the exciting new features and the limitations of the model, as well as his hopes for widespread use in the PD research community.

 

Factors Affecting Drug Distribution Through Infusion

The Infusion Physics Study Group, a multidisciplinary effort spearheaded by the Kinetics Foundation to research and utilize Convection Enhanced Delivery, has posted two new responses (packed with data!) to the Research Question "How can we improve brain delivery of trophic factors?" Read the latest in their series of new research: "Factors Affecting Drug Distribution Through Infusion."

 

Placebo Response Workshop

The current gold standard methodology for testing the efficacy of experimental Parkinson’s disease therapeutics involves the placebo-controlled study design.  However, positive placebo responses have been reported in a number of PD trials, complicating the interpretation of efficacy results. MJFF and the Davis Phinney Foundation sponsored a workshop held in New York to discuss the mechanism of the placebo response and how to move forward in future clinical trials.

Reply